In a turbulent market environment, Vincerx Pharma, Inc. (VINC) stock has reached its 52-week low, trading at $1.3. According to InvestingPro analysis, the company maintains a healthy current ratio of ...
Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...
UFC Vegas 102 continues with a fight between Ismael Bonfim and Nazim Sadykhov. Check out our UFC odds series for our ...
Vincerx Pharma announces early results for VIP943 and VIP236 in Phase 1 studies targeting hard-to-treat cancers, with complete responses seen in AML and HR-MDS patients and encouraging disease ...
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to ...
Hosted on MSN15d
VINC stock touches 52-week low at $1.62 amid market challengesIn a turbulent market environment, VINC stock has reached its 52-week low, trading at $1.62, with technical indicators from InvestingPro showing the stock in oversold territory. This price level ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback